Efficacy of canakinumab in mild or severe COVID‐19 pneumonia

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia

Abstract Background Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to treat SARS‐CoV‐2 infection. In this...

Full description

Bibliographic Details
Main Authors: Falasca Katia, Di Penta Myriam, Claudio Ucciferri, Antonio Auricchio, Marta Di Nicola, Michele Marchioni, Celletti Eleonora, Sabatini Emanuela, Francesco Cipollone, Jacopo Vecchiet
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Immunity, Inflammation and Disease
Subjects:
IL1‐β
monoclonal antibody
safety
SARS COV2
therapy
Online Access:https://doi.org/10.1002/iid3.400

Internet

https://doi.org/10.1002/iid3.400

Similar Items